Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant and Adjuvant Therapy in Stage III NSCLC
NCT04865705Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04865705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865705.